A NANOSTRUCTURE FROM ASCORBYL PALMITATE BASED-ADJUVANT BOOSTS ADAPTIVE IMMUNITY BY INDUCING AN INFLAMMATORY EFFECT AT THE INJECTION SITE, BOTH PROPERTIES REQUIRE THE ADAPTOR PROTEIN MYD88

M F SÁNCHEZ VALLECILLO; G ULLIO GAMBOA; M MINGUITO DE LA ESCALERA; S D PALMA; L GONZÁLEZ-CINTADO; A L CHIODETTI; M V AGUIRRE; C LUQUE BUTELER; G MORÓN; D A ALLEMANDI; C ARDAVÍN; M C PISTORESI-PALENCIA; B A MALETTO

Mar del Plata

Congreso; LXII reunión de la Sociedad Argentina de Inmunología; 2014

The approved adjuvants for human use induce weak cellular immune responses in subunit vaccines. Thus, the development of new adjuvant strategies is critical. Recently, we have showed that a nanostructure from 6-O-ascorbyl palmitate (Coa-ASC16), used as a platform to formulate CpG-ODN, improved notably its adjuvanticity; one of the possible mechanisms involved is the controlled release given by Coa-ASC16 formulation. In addition, Coa-ASC16 elicits local inflammatory response but how it is sensed is little understood. Here, we begin to understand the underlying mechanisms on the interaction between Coa-ASC16 and immune system after i.p injection. We previously found that the inflammatory response elicited by Coa-ASC16 (neutrophils and monocytes recruitment and IL-1β, IL-6, IL-12) was dependent on MyD88 adaptor protein. TLR2, TLR4 and TLR7 were dispensable for this inflammatory effect. The administration of Coa-ASC16 was associated with the local release of double-stranded DNA (Coa-ASC16 vs control 2.5±0.5 vs 0.5±0.1 (μg/mL) (p